BOMBAY, Inde et DUBLIN, 28 septembre 2023 /PRNewswire/ — Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) (« Cosmo ») et Glenmark Specialty S.A., une filiale de Glenmark Pharmaceuticals Ltd. (« Glenmark »), ont annoncé aujourd’hui la signature d’accords de distribution et de licence…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.